PPH Fact Sheet: VanEck Pharmaceutical ETF
Share
$114.85
close, Nov 20, 2026
Over the year to Nov 19, 2026, PPH returned +18.4% in total and charged 0.36% a year.
- 1-year total return
- +19.2%
- to Nov 20, 2026
- Expense ratio
- 0.36%
- a year
- Net assets
- $1.0bn
- on Nov 19, 2026
Growth of $10,000, 1 year
PPH $11,835 +18.4% · ACWI $10,902 +9.0% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−0.6%
3 months−1.2%
Year to date+13.2%
1 year+19.2%
3 years+56.7%
5 years+70.0%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
Eli Lilly & Co22.99%
Merck & Co Inc11.58%
Novo Nordisk A/S5.46%
Mckesson Corp5.13%
Pfizer Inc4.74%
Cencora Inc4.54%
Teva Pharmaceutical Industries Ltd4.40%
Bristol-Myers Squibb Co4.33%
Gsk Plc4.23%
Abbvie Inc3.74%
PPH top ten by weight, 71.1% of the fund, of its 25 equity positions, from the holdings published by its issuer for Nov 19, 2026.
Facts
Equity fund · Tracks the MVIS US Listed Pharmaceutical 25 Index · Benchmark Its own holdings, as of Nov 19, 2026